OMNIPHYX™ Neuro

Non-Invasive Multimodal Physiological Instability Detection for Early Cognitive Decline

OMNIPHYX™ Neuro is a system-focused physiological intelligence architecture designed to identify early neurophysiological instability patterns associated with cognitive decline and neurodegenerative progression. It integrates multimodal signal acquisition, harmonization, coherence-based instability modeling, and longitudinal trend reporting.

Non-invasive Continuous monitoring Multimodal fusion Coherence + drift detection Longitudinal stability scoring Grant / institutional posture IP-safe public overview

Primary focus

Early cognitive decline monitoring and neurodegenerative instability tracking (informational), structured for pilots, research validation, and institutional evaluation.

What it produces

Stability Index, longitudinal Trend Reports, and threshold-based Instability Alerts designed for monitoring and research workflows (non-diagnostic).

How it’s used

Institutional pilots, consortium studies, trial enrichment, and longitudinal monitoring programs, with phased validation and measurable endpoints.

The clinical gap

Late detection problem: Neurodegenerative disorders are frequently identified after significant decline.
Episodic assessment: Many workflows rely on infrequent cognitive testing or single-timepoint snapshots.
Resource burden: Imaging and biomarker pathways can be expensive, invasive, or limited in availability.
Network gap: There is limited scalable infrastructure for continuous, non-invasive instability monitoring.
Pilot need: Institutions need structured, measurable pilots to validate novel monitoring approaches.

OMNIPHYX™ is designed to support earlier monitoring signals and longitudinal tracking to improve timing for intervention and research enrollment.

The solution

Multimodal acquisition: Captures multiple physiological signal domains relevant to stability and resilience.
Signal harmonization: Aligns and normalizes inputs for stable cross-signal comparison.
Instability modeling: Uses coherence analysis and drift detection over longitudinal windows.
Risk tier outputs: Generates informational tiers and trend reports for monitoring workflows.
Validation posture: Designed for phased pilots with measurable endpoints and reproducible reporting.

Public materials exclude proprietary model parameters and signal weighting. The architecture is presented as a system-layer overview.

System architecture overview

OMNIPHYX™ Neuro operates through structured layers, separating acquisition, harmonization, modeling, and reporting to support reproducibility, validation, and institutional pilot workflows.

Outputs are informational: Stability Index, Instability Alerts, and longitudinal Trend Reports. This page does not provide diagnostic claims.

Signal acquisition

Non-invasive multimodal physiological signal capture for continuous or scheduled monitoring.
Supports pilot workflows across home, clinic, and research settings (as defined by the institution).
Public overview excludes sensor specifics and proprietary capture implementation.

Harmonization

Noise filtration, artifact control, and quality gating.
Temporal alignment across modalities to maintain comparability.
Cross-signal normalization enabling stable longitudinal windowing.

Instability modeling

Coherence analysis and divergence mapping across signal domains.
Drift detection over defined longitudinal windows.
Produces informational scores, thresholds, and trend reports suitable for pilot validation.

Primary use case

Early cognitive decline monitoring (informational): identify instability signatures that may correlate with early decline patterns.
Preclinical tracking: support earlier monitoring pathways to improve intervention timing.
Longitudinal stability: track stability trends and detect meaningful deviations over time.
Research readiness: structured outputs that support pilot study design and reporting.

Secondary applications

Progression monitoring (informational): observe stability trend shifts in diagnosed populations.
Clinical trial enrichment: support cohort stratification and monitoring endpoints.
Intervention response: track stability changes pre/post interventions.
Multi-site validation: consistent reporting for consortium and institutional partners.

Development pathway

Phase I — Prototype refinement: finalize system architecture, quality gating, and reporting outputs.
Phase II — Pilot feasibility: single-site cohort pilot with measurable endpoints and reporting.
Phase III — Multi-site validation: consortium expansion, reproducibility testing, and comparative cohorts.
Phase IV — Regulatory evaluation: pathway assessment depending on intended claims and jurisdiction.

Each phase is designed around measurable deliverables, risk controls, and partner-approved protocols.

Funding alignment

EU Horizon Health: neurodegeneration, aging, digital health consortia and validation programs.
NIH / NIA: Alzheimer’s and related dementias research and monitoring technology tracks.
Institutional pilots: universities, hospitals, and research institutes conducting early monitoring studies.

OMNIPHYX™ can participate as a partner or lead depending on call structure and consortium readiness.

Intellectual property posture

Proprietary scope: system architecture, coherence modeling, instability scoring, and reporting frameworks.
Public boundary: no disclosure of algorithms, weighting, parameters, model internals, or engineering schematics.
Partner pathway: qualified parties may request a technical package under NDA for evaluation.

This public page is intentionally written to be safe for IPO/investor review while remaining institution-ready and fundable.

Contact

For institutional pilots, consortium participation, funding-aligned collaborations, or partner inquiries:

Lathell Sancho
Founder — Lathell Nutraceuticals LLC (United States)
l.sancho@lathellnutraceuticalsllc.com
+1 (702) 413-4481

Suggested subject line: “OMNIPHYX Neuro — Partner Request”